Restore Vision, Inc., one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem
Restore Vision, Inc., one of our portfolio companies in Japan, was selected as one of the supported projects in "Strengthening Program for Pharmaceutical Venture Ecosystem in 2023” by Japan Agency for Medical Research and Development (AMED).
In this program, AMED provides matching financial support for the drug development of selected projects on the condition that an equity investment is executed by an AMED certified venture capital firm that provides hands-on support focusing on drug discovery and development. Remiges Ventures, a lead investor for Restore Vision through the recent financing round, was selected as one of the certified venture capital firms in 2022.
Restore Vision, Inc. is a private biotech company developing a visual restoration gene therapy for blindness caused by retinal disorders, using a clinical application of optogenetics technology based on promising results of joint research between Keio University School of Medicine and Nagoya Institute of Technology. This program will accelerate the development of the company’s lead program, RV-001.
For more detailed information please visit the above AMED web pages.